A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy
A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy
This study will evaluate the long-term safety and tolerability of elexacaftor
 (ELX)/tezacaftor (TEZ)/ ivacaftor (IVA) triple combination (TC) in subjects with cystic
 fibrosis (CF) who are homozygous for F508del.
Key Inclusion Criteria:

 -  Completed study drug treatment in parent study (VX18-445-109); or had study drug
 interruption(s) in parent study but completed study visits up to the last scheduled
 visit of the Treatment Period in the parent study

 Key Exclusion Criteria:

 -  History of study drug intolerance in parent study

 Other protocol defined Inclusion/Exclusion criteria may apply